Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1112

1.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
2.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
3.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
4.

TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.

Handelsman Y, Shapiro MD.

Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Review.

PMID:
27819772
5.

Nonstatin therapies for management of dyslipidemia: a review.

Sando KR, Knight M.

Clin Ther. 2015 Oct 1;37(10):2153-79. doi: 10.1016/j.clinthera.2015.09.001. Epub 2015 Sep 26. Review.

PMID:
26412799
6.
7.

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].

Bajnok L.

Orv Hetil. 2014 Jan 12;155(2):62-8. doi: 10.1556/OH.2014.29797. Review. Hungarian.

PMID:
24389322
8.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

9.

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Chapman MJ, Le Goff W, Guerin M, Kontush A.

Eur Heart J. 2010 Jan;31(2):149-64. doi: 10.1093/eurheartj/ehp399. Epub 2009 Oct 12. Review.

10.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
11.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

13.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

15.

Lipoprotein(a), cardiovascular disease, and contemporary management.

Jacobson TA.

Mayo Clin Proc. 2013 Nov;88(11):1294-311. doi: 10.1016/j.mayocp.2013.09.003. Review.

PMID:
24182706
16.

The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.

Hajhosseiny R, Sabir I, Khavandi K, Wierzbicki AS.

Clin Pharmacol Ther. 2014 Jul;96(1):64-73. doi: 10.1038/clpt.2014.76. Epub 2014 Apr 3. Review.

PMID:
24699033
17.

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Jacobson TA.

Int J Clin Pract. 2011 Jan;65(1):82-101. doi: 10.1111/j.1742-1241.2010.02547.x. Epub 2010 Nov 24. Review.

PMID:
21105969
18.

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

Miyares MA, Davis K.

Vasc Health Risk Manag. 2012;8:483-93. doi: 10.2147/VHRM.S29010. Epub 2012 Aug 23. Review.

19.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Ito MK.

Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11. Review.

PMID:
26296750
20.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282

Supplemental Content

Support Center